Biohaven partners with Ono in $100m IgG degrader deal

​

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.

The post Biohaven partners with Ono in $100m IgG degrader deal appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.